NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
ID: 326888Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) to support innovative research projects that include at least one clinical trial. This funding opportunity aims to facilitate exploratory and developmental studies that may involve significant risk but have the potential to lead to breakthroughs in biomedical, behavioral, or clinical research. Eligible applicants include a diverse range of organizations, such as higher education institutions, nonprofits, and foreign entities, with a combined budget cap of $275,000 for a maximum two-year project period, and annual requests not exceeding $200,000. Interested parties should submit their applications by January 7, 2025, and can direct inquiries to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further assistance.

    Point(s) of Contact
    Files
    Title
    Posted
    The NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) seeks to facilitate innovative research by funding exploratory and developmental projects that include at least one clinical trial. Participating NIH Institutes and Centers (ICs), such as the National Institute of Mental Health, encourage applications focusing on novel scientific ideas or methodologies that may lead to significant advancements in biomedical or behavioral research. Eligible applicants encompass a wide range of organizations, including higher education institutions, nonprofits, and foreign entities. A combined budget cap of $275,000 is set for a maximum two-year project period, with annual requests not exceeding $200,000. The application process requires adherence to detailed submission instructions and compliance with NIH policies regarding human subjects and clinical trials. Notably, this funding opportunity emphasizes innovation and the development of novel tools or techniques, aiming to foster groundbreaking research that might not be supported by traditional grant mechanisms. Reviewers will assess submissions based on scientific merit, significance, innovation, and the qualifications of the investigators. This grant aligns with NIH's mission to promote research that meets public health needs and addresses critical barriers to scientific progress.
    Similar Opportunities
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) to support innovative biomedical and clinical research projects. This grant aims to foster exploratory research that may involve significant risks but has the potential for breakthroughs or the development of novel methodologies in health-related fields. The program is crucial for advancing research that addresses pressing health challenges and encourages applications that present new scientific ideas distinct from traditional R01 projects. Eligible applicants include a wide range of institutions, including higher education institutions, nonprofits, and for-profit organizations, both domestic and foreign, with a budget limit of $275,000 over two years and a maximum request of $200,000 in any single year. Interested parties should submit their applications electronically by January 7, 2025, and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further assistance.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21), aimed at supporting innovative early-stage research projects in the biomedical, behavioral, and clinical fields. This funding opportunity is specifically designed for basic experimental studies involving human participants, with a focus on developing novel techniques or methodologies that can significantly advance scientific understanding. Eligible applicants, including small businesses and various institutions, can receive funding of up to $275,000 over a two-year period, with applications accepted on a rolling basis until the close date of January 7, 2025. For further details, interested parties can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PA-20-196.html.
    NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Mental Health (NIMH), is offering the Exploratory/Developmental Research Grant (R21), which aims to support high-risk and innovative research projects that align with the mission of advancing mental health research. This grant is specifically designed for the early stages of research that may lead to significant breakthroughs in clinical and biomedical fields related to mental health, with a funding limit of $275,000 over a two-year period. Eligible applicants include a diverse range of organizations such as higher education institutions, non-profits, and tribal governments, emphasizing the importance of innovative approaches in addressing critical barriers in mental health research. Interested parties should note that applications are due by January 7, 2025, and must adhere to NIH guidelines, with further inquiries directed to grantsinfo@nih.gov.
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Bioengineering Research Grants (EBRG) under the R21 mechanism, aimed at fostering innovative engineering solutions to advance biomedical research. This funding opportunity encourages applications from a diverse range of organizations, including higher education institutions and nonprofits, to support exploratory projects that demonstrate feasibility and potential utility in addressing critical challenges in biomedical research and clinical care delivery, without involving clinical trials. The initiative emphasizes collaboration between quantitative and physical scientists and biomedical researchers, aiming to facilitate early-stage developments that can lead to significant advancements in medical technologies and methods. The funding ceiling is set at $275,000 over two years, with applications due by January 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-090.html.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Exploratory/Developmental Bioengineering Research Grants (EBRG) under the R21 funding mechanism, aimed at fostering innovative projects that address significant biomedical challenges. This funding opportunity encourages applications that explore new capabilities or improvements in biomedical research, clinical care delivery, and accessibility, with a focus on groundbreaking engineering research and collaboration across diverse scientific disciplines. Eligible applicants include higher education institutions, nonprofits, and small businesses, with a budget cap of $275,000 over two years, and applications are due by January 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-091.html.
    Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional) to support innovative and exploratory research projects in neuroscience. This grant aims to facilitate early-stage studies that assess novel avenues of investigation, particularly those that may involve significant risk but hold the potential for breakthroughs in understanding neuroscience or developing new methodologies. Eligible applicants include a wide range of organizations such as educational institutions, nonprofits, and tribal governments, with funding available up to $200,000 over two years. Interested parties should submit their applications by January 7, 2025, and can find additional information and application guidelines at the NIH website or contact grantsinfo@nih.gov for assistance.
    NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional) to support innovative research aimed at addressing minority health and health disparities in the United States. This grant invites applications for short-term exploratory projects that can either pioneer new advancements or build upon previous findings, with a maximum funding amount of $275,000 available for a two-year project period, limiting annual requests to $200,000. The program emphasizes the importance of diverse representation among applicants and encourages partnerships with relevant stakeholders, focusing on NIH-designated health disparity populations through various research methodologies. Interested applicants can find more information and submission guidelines at the provided link, with the application deadline set for May 7, 2026. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled “Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed),” aimed at supporting exploratory research for innovative biomedical technologies. This initiative focuses on high-risk projects that have not yet established feasibility, specifically targeting the development of tools such as laboratory instruments, algorithms, and chemical reagents, while excluding applications that address specific biological questions or present existing proof of concept data. Eligible applicants can request funding of up to $275,000 over two years, with a maximum of $200,000 in any single year, and applications are due by May 7, 2025. For further details, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or refer to the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-126.html.
    Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)," aimed at supporting studies that address barriers to the adoption and sustainability of evidence-based health interventions, particularly in underserved communities. The initiative encourages research that promotes equitable access to effective practices and explores methods for discontinuing ineffective or harmful interventions, emphasizing the importance of contextual factors and multidisciplinary collaboration. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and tribal governments, with a maximum funding amount of $275,000 and a project period of up to two years. Interested parties can find more information and submit inquiries via the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with applications due by May 7, 2025.